Kojima, Yuki
Sudo, Kazuki
Yoshida, Hiroshi
Yazaki, Shu
Tokura, Momoko
Mizoguchi, Chiharu
Okuma, Hitomi S.
Kita, Shosuke
Yamamoto, Kasumi
Nishikawa, Tadaaki
Noguchi, Emi
Shimoi, Tatsunori
Tanase, Yasuhito
Uno, Masaya
Ishikawa, Mitsuya
Kato, Tomoyasu
Koyama, Kumiko
Kobayashi, Maki
Kakegawa, Tomoya
Fujiwara, Yasuhiro
Yonemori, Kan
Article History
Received: 30 October 2022
Accepted: 30 December 2022
First Online: 3 February 2023
Declarations
:
: The study was approved by the Institutional Review Board of the National Cancer Center, Tokyo, Japan (Approval Number: 2020–003). Written informed consent was waived because of the retrospective design.
: Not applicable.
: Yuki Kojima, Kazuki Sudo, Hiroshi Yoshida, Tatsunori Shimoi, Shu Yazaki, Momoko Tokura, Hitomi S. Okuma, Chiharu Mizoguchi, Shosuke Kita, Kasumi Yamamoto, Yasuhito Tanase, Masaya Uno, Mitsuya Ishikawa, and Tomoyasu Kato have nothing to disclose. Tadaaki Nishikawa reports personal fees from Takeda Pharmaceutical Company, Eisai, and AstraZeneca outside the submitted work. Emi Noguchi reports personal fees from Pfizer, Taiho, Eli Lilly, AstraZeneca, Chugai, and Eisai outside the submitted work. Yasuhiro Fujiwara reports personal fees from AstraZeneca, Chugai, Daiichi Sankyo, Bristol-Myers, SRL, and Santen outside the submitted work. Kan Yonemori reports personal fees from Pfizer, AstraZeneca, Eisai, Takeda Pharmaceutical Company, Chugai, Ono Pharmaceutical Company, Novartis, and Daiichi Sankyo outside the submitted work. Kumiko Koyama, Maki Kobayashi, and Tomoya Kakegawa are employees of Daiichi Sankyo or Daiichi Sankyo RD Novare and declare no potential conflict of interest and funding.